## Contents

Application of Additional Terms and Conditions ................................................................. 3  
MRC AC 1 Accountability & Responsibilities of the Research Organisation (in addition to RGC 2) ....... 3  
MRC AC 2 Registered Healthcare Professionals ................................................................. 3  
MRC AC 3 Mouse Strains ................................................................................................. 3  
MRC AC 4 Human Participants in Research .................................................................... 3  
MRC AC 5 Clinical Trials ............................................................................................... 4  
MRC AC 6 Stem Cells .................................................................................................... 4  
MRC AC 7 Data Protection (in addition to RGC 2.2) ....................................................... 4  
MRC AC 8 Data Sharing ................................................................................................. 4  
MRC AC 9 Open Access Policy - Publication Repositories ............................................ 4  
MRC AC 10 MRC Industry Collaboration Framework ..................................................... 5
Application of MRC Additional Terms and Conditions

As with the UKRI Standard Terms and Conditions, in these MRC Additional Terms and Conditions the words “We”, “Our” or “Us” refer to the Medical Research Council (MRC), as the awarding council and “You” or “Your” refer to the Research Organisation in receipt of the Grant. Other key terms used are set out in the Definitions at Annex A in the UKRI Standard Terms and Conditions.

These Additional Terms and Conditions, together with the UKRI Standard Terms and Conditions https://www.ukri.org/apply-for-funding/before-you-apply/your-responsibilities-if-you-get-funding/meeting-ukri-terms-and-conditions-for-funding/ comprise the Grant Terms and Conditions on which UKRI awards the MRC Grant to the Research Organisation. We reserve the right to vary these Additional Terms and Conditions.

Additional Terms and Conditions of Grant

MRC AC 1 Accountability & Responsibilities of the Research Organisation (in addition to RGC 2)

MRC AC 1.1 You are responsible for ensuring the Project is carried out in accordance with all applicable operational, legislative and ethical conditions and requirements relating to medical research.

MRC AC 1.2 You are responsible for obtaining all necessary licenses, approvals, permissions and consent for the research and ensuring no research requiring approvals starts until they are in place.

MRC AC 1.3 You must demonstrate to Us on request that required approvals are in place, or were in place before research started. We reserve the right to audit this at any time without prior notice.

MRC AC 2 Registered Healthcare Professionals

MRC AC 2.1 You must ensure all registered healthcare professionals supported by Our funding are aware they are individually responsible for maintaining appropriate professional indemnity insurance, We will not meet the costs of such cover.

MRC AC 2.2 Registered healthcare professionals supported by Our funding may not work more than the agreed time commitment for clinical duties.

MRC AC 2.3 Any honorary contracts required by registered healthcare professionals must be obtained prior to the start of the Project.

MRC AC 2.4 You must abide by the ‘UK clinical academic training in medicine and dentistry: principles and obligations’ (https://www.nihr.ac.uk/documents/clinical-principles-and-obligations-march-2018/22067) and the ‘UK clinical academic training for nurses, midwives, AHPs and other health and care professionals: principles and obligations’ (https://www.nihr.ac.uk/documents/uk-clinical-academic-training-for-nurses-midwives-and-other-professionals-allied-to-medicine-principles-and-obligations/27109)

MRC AC 3 Mouse Strains

Where research involves mouse strains, the Grant Holder must contact the MRC mouse Frozen Embryo and Sperm Archive (FESA) at Harwell before research starts, regarding mouse strains to be engineered, or characterised by the project. You should deposit these strains with FESA wherever possible https://www.har.mrc.ac.uk/mlc-services/archiving-and-distribution/.

MRC AC 4 Human Participants in Research

Research involving human participants must be undertaken in accordance with Our policies and guidance https://www.ukri.org/councils/mrc/guidance-for-applicants/policies-and-guidance-for-researchers/supporting-good-research-practice/#ethics
MRC AC 5 Clinical Trials
AC 5.1 Where research involves MRC-funded clinical trials, Grant Holders must act in accordance with Our policies on research sponsorship https://www.ukri.org/councils/mrc/guidance-for-applicants/policies-and-guidance-for-researchers/clinical-research-governance/clinical-trials-regulations/.

AC 5.2 Research involving MRC-funded clinical trials conducted in lower and middle income countries (LMICs) must follow Our guidelines for oversight and management of global health trials https://www.ukri.org/publications/management-of-global-health-trials-mrc-guidelines/.

AC 5.3 You must establish an independent Trial Steering Committee to oversee the conduct of the trial. Other governance and oversight arrangements must be agreed with Us, such as requirement for a Data Monitoring Committee.

AC 5.4 Clinical trials must be registered with the ISRCTN Registry https://www.isrctn.com/ and receive an ISRCTN number. The ISRCTN number must be used in publications and added to Researchfish within 12 months of the trial starting. If You fail to provide the ISRCTN number when requested the Grant will be suspended. You must update the ISRCTN registry regularly and report or publish trial results within 24 months of study completion.

AC 5.5 Trial results should be reported in accordance with the recommendations in the CONSORT statement http://www.consort-statement.org/. Before results are published, they must be discussed by the Trial Steering Committee. If You fail to publicly report results from an MRC-funded trial, We will not permit other related MRC awards to start until these results are reported.

AC 5.6 Any contribution to an MRC-funded trial by another body, such as a pharmaceutical company (donation of drugs etc.), must be the subject of a collaboration agreement between the parties (see AC 10).

MRC AC 6 Stem Cells
AC 6.1 Where research involves human stem cell lines (both embryonic and adult), Grant Holders must abide by the UK Code of Practice for the use of Human Stem Cell lines https://www.ukri.org/publications/the-use-of-human-stem-cell-lines-code-of-practice-2010/.

AC 6.2 Where research involves human embryonic stem cells (hESCs), Grant Holders must deposit a sample of every human embryonic stem cell line derived with Our funding in the UK Stem Cell Bank. Applications to deposit, access banked hESC lines, or use hESC lines from the UK or overseas must be approved by the Steering Committee for the UK Stem Cell Bank https://www.ukri.org/councils/mrc/guidance-for-applicants/policies-and-guidance-for-researchers/uk-stem-cell-bank-steering-committee/.

MRC AC 7 Data Protection (in addition to RGC 2.2)
All researchers handling confidential information must have clearly established responsibilities to maintain confidentiality, formalised within Your policies or through professional codes of conduct.

MRC AC 8 Data Sharing

MRC AC 9 Open Access Policy - Publication Repositories
All MRC funded researchers must comply with UKRI open access requirements. To comply with the UKRI Policy on Open Access (see RGC 12.4 and https://www.ukri.org/manage-your-award/publishing-your-research-findings/making-your-research-publications-open-access/) the Grant Holder must deposit all publications within the scope of the policy in Europe PMC. This must be the Author’s Accepted Manuscript (or Version of Record, where the publisher permits). Deposit must occur at the time of final publication, as defined in Annex 1 of the UKRI Open access policy. This applies both during and after the period of funding.
For more information see [https://www.ukri.org/councils/mrc/guidance-for-applicants/policies-and-guidance-for-researchers/open-access-policy/](https://www.ukri.org/councils/mrc/guidance-for-applicants/policies-and-guidance-for-researchers/open-access-policy/)

**MRC AC 10 MRC Industry Collaboration Framework**

For Industry Collaboration Framework awards You must provide Us with a copy of the collaboration agreement, signed by all partners, within 3 months of the date of this Offer Letter and prior to the Official Start Date. The grant will not start until this document has been submitted and approved by Us [https://www.ukri.org/councils/mrc/guidance-for-applicants/types-of-funding-we-offer/mrc-industry-collaboration-framework-icf/](https://www.ukri.org/councils/mrc/guidance-for-applicants/types-of-funding-we-offer/mrc-industry-collaboration-framework-icf/)